Pedro F S Freitas
Overview
Explore the profile of Pedro F S Freitas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
5
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
da Silva I, de Amorim L, Piredda G, Mass-Lindenbaum M, de Moraes F, Freitas P, et al.
Clin Transl Oncol
. 2025 Feb;
PMID: 39987332
Purpose: Treatment for metastatic castration-resistant prostate cancer (mCRPC) includes chemotherapy and inhibition of the androgen receptor pathway. However, the optimal treatment sequence in this scenario is not yet fully understood....
2.
Khandekar A, Porto J, Daher J, Freitas P, Asselman D, Suarez M, et al.
BJUI Compass
. 2025 Jan;
5(12):1263-1268.
PMID: 39744073
Objectives: The objectives of this study are to compare the accuracy of warm ischemia times (WITs) derived by a surgical artificial intelligence (AI) software to those documented in surgeon operative...
3.
Delgado J, Porto J, Bhatia A, Raymo A, Blachman-Braun R, Ajami T, et al.
World J Urol
. 2024 Dec;
43(1):53.
PMID: 39739024
Purpose: In patients with prostate cancer (PCa), focal therapy with High-Intensity Focused Ultrasound (HIFU) combined with benign prostatic hyperplasia (BPH) surgery has been used to improve immediate post-operative voiding symptoms....
4.
Kimbel I, Wallaengen V, Zacharaki E, Breto A, Algohary A, Carbohn S, et al.
Acad Radiol
. 2024 Dec;
PMID: 39694787
Rationale And Objectives: Active surveillance (AS) is the preferred management strategy for low-risk prostate cancer. This study aimed to evaluate the impact of Habitat Risk Score (HRS), an automated approach...
5.
Ajami T, Yu H, Porto J, Prakash N, Williams A, Avda Y, et al.
Eur Urol Focus
. 2024 Dec;
PMID: 39665894
Background And Objective: Prostate cancer (PC) heterogeneity can result in sampling discrepancies during biopsy, leading to inaccurate molecular classifications that affect treatment decisions. We evaluated transcriptomic profile variability between multiparametric...
6.
Nahar B, Ajami T, Williams A, Prakash N, Khandekar A, Freitas P, et al.
Eur Urol Focus
. 2024 Nov;
PMID: 39613544
Background And Objective: Focal therapy is increasingly being used as a treatment for localized prostate cancer (PC). Our aim was to evaluate oncological outcomes, recurrence patterns, and survival after high-intensity...
7.
Freitas P, Abdshah A, McKay R, Sharifi N
Nat Rev Urol
. 2024 Nov;
PMID: 39543357
Androgen receptor stimulation by testosterone and dihydrotestosterone is crucial for prostate cancer progression. Despite the initial effectiveness of androgen deprivation therapy (ADT), castration-resistant prostate cancer eventually develops in most men....
8.
Freitas P, Blachman-Braun R, Soodana-Prakash N, Williams A, Ritch C, Punnen S, et al.
World J Urol
. 2024 Sep;
42(1):551.
PMID: 39347950
Purpose: Recent advancements in screening, prostate MRI, robotic surgery, and active surveillance have influenced the profile of patients undergoing radical prostatectomy (RP). We sought to examine their impact on trends...
9.
Freitas P, Vidal R, Watanabe C, Arap M
Transl Androl Urol
. 2023 Feb;
12(1):5-8.
PMID: 36760868
No abstract available.
10.
Freitas P, Barbosa J, Andrade H, Arap M, Mitre A, Nahas W, et al.
Urology
. 2021 May;
156:e66-e73.
PMID: 34033827
Objectives: To systematically summarize the available evidence concerning the impact of pyeloplasty on symptoms and differential renal function (DRF) in adults with unilateral UPJO in poorly functioning kidneys (PFK), and...